Abstract Number: 0708 • ACR Convergence 2021
Cardiovascular Risk in Myositis Patients Compared to General Population – Preliminary Data from a Single-centre Cross-sectional Study
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are associated with systemic inflammation, limited mobility, and glucocorticoid treatment, which can have a negative impact on metabolic disease, atherogenesis,…Abstract Number: 1007 • ACR Convergence 2021
Vascular Deposition of Oxidized LDL Is Increased in Children with Untreated Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic vasculopathy associated with metabolic derangements and possible increased risk for premature atherosclerosis. Oxidation of low-density lipoprotein (LDL) in…Abstract Number: 0683 • ACR Convergence 2021
Predictors of Rapidly Progressive Interstitial Lung Disease and Mortality in Patients with Autoantibodies Against Melanoma Differentiation-Associated Protein 5 Dermatomyositis
Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA5) positive dermatomyositis (DM) is associated with rapidly progressive interstitial lung disease (RP-ILD) and high mortality. This multi-centre retrospective study…Abstract Number: 0709 • ACR Convergence 2021
Lower HDL-associated Apolipoprotein A-I Levels Associate with Presence of Calcinosis in Adult Dermatomyositis
Background/Purpose: Calcinosis is a sequelae of juvenile and adult dermatomyositis (DM) associated with significant morbidity and poor quality of life. It is hypothesized that inflammatory…Abstract Number: 1022 • ACR Convergence 2021
Incidence of Antisynthetase Syndrome and Risk of Malignancy in a Population-based Cohort (1998-2019)
Background/Purpose: The antisynthetase syndrome (ASSD) is a distinct subgroup of the idiopathic inflammatory myopathies characterized by myositis, interstitial lung disease, inflammatory arthritis, Raynaud’s phenomenon and…Abstract Number: 0684 • ACR Convergence 2021
Extended Report: Successful Treatment anti-MDA5 Antibody-positive Interstitial Lung Disease with Plasma Exchange Therapy
Background/Purpose: This study was extended report from our previous study that “Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy” (Rheumatology…Abstract Number: 0710 • ACR Convergence 2021
Patients with Recent Onset, Active Polymyositis (PM), Dermatomyositis (DM) and Antisynthetase Syndrome (ASS) Have Reduced Muscle Endurance but Not Reduced Muscle Strength Compared to Patients with Established, Low-active Disease
Background/Purpose: To analyze for differences in quadriceps maximal isometric voluntary contraction (MVIC), muscle endurance (ME), muscle mass and fat mass (m. vastus lateralis, mid-thigh) in…Abstract Number: 1025 • ACR Convergence 2021
Survival of Patients with Idiopathic Inflammatory Myopathy in Slovenia
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare systemic diseases associated with significant morbidity and mortality. The aim of our study was to…Abstract Number: 0686 • ACR Convergence 2021
Is It Useful to Assess Muscle Involvement with Positron Emission Tomography in Patients with Idiopathic Inflammatory Myositis? A Case-Control Study
Background/Purpose: Multiple diagnostic methods have been used to investigate muscle involvement in patients with idiopathic inflammatory myositis (IIM) such as electromyography (EMG) and muscle MRI.…Abstract Number: 0711 • ACR Convergence 2021
Suppression of HDL-associated Apolipoprotein A-I (apoA-I) Levels in Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: Patients with idiopathic inflammatory myopathies have accelerated vascular disease, which contributes to higher disease morbidity and mortality. Apolipoprotein A-I (apoA-I) is the major protein…Abstract Number: 1090 • ACR Convergence 2021
Contribution of Scleroderma/Myositis-Related Antibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 134 Patients from a Single Referral Center
Background/Purpose: Immunoblot assays are increasingly used in clinical practice as part of the diagnostic armamentarium of systemic autoimmune rheumatic diseases (SARDs). Our aim was to…Abstract Number: 0688 • ACR Convergence 2021
Standardized Prevalence Ratios of Cancer in Idiopathic Inflammatory Myositis
Background/Purpose: Whether the likelihood of a cancer diagnosis in idiopathic inflammatory myopathy (IIM) patients differs by autoantibody type is not fully characterized. To inform cancer…Abstract Number: 0712 • ACR Convergence 2021
Immune Checkpoint Inhibitor-related Myotoxicity : Musculoskeletal and/or Neuromuscular Junction Disorder ?
Background/Purpose: Immune checkpoint inhibitor (ICI)-related adverse events (irAE) recently emerged as new diseases in the field of auto-immunity. Among them, ICI-related myotoxicity has the highest…Abstract Number: 1164 • ACR Convergence 2021
A Survey of Treatment Satisfaction with Intravenous Immunoglobulin Among Patients with Inflammatory Myositis
Background/Purpose: Intravenous Immunoglobulin (IVIg) is used to treat rheumatic conditions such as Inflammatory Myositis. Subcutaneous Immunoglobulin (SCIg) is an alternative route of administering Immunoglobulin. Studies…Abstract Number: 0690 • ACR Convergence 2021
Impact of Achieving 2016 ACR/EULAR Response Criteria on Patient Centered Outcome Measures in Myositis
Background/Purpose: The 2016 ACR/EULAR Myositis Response Criteria represent a composite measure that is increasingly being used as a primary end point in myositis clinical trials.…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 28
- Next Page »